Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference
14 Settembre 2020 - 8:00AM
Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual
Global Investment Conference
Oxurion NV to Present at H.C. Wainwright
& Co 22nd Annual Global Investment
Conference
Leuven, Belgium ,
14 September 2020 – 8.00 A.M. CET – Oxurion NV (Euronext
Bxls: OXUR), a biopharmaceutical company developing next generation
standard-of-care therapies for diabetic macular edema (DME),
announces today that the Company’s CEO, Dr.Patrik De Haes, will be
presenting at HC Wainwright & Co’s 22nd Annual Global
Investment Conference on Wednesday, September 16th, 2020 at 10:00
a.m. ET.
The presentation will cover Oxurion’s emerging
DME franchise designed to improve the treatment outcomes of all DME
patients. The Company’s franchise is based around THR-149 and
THR-687, two novel drug candidates with different, non-VGEF modes
of action. DME is a significant global healthcare problem and
the major cause of vision loss in diabetic patients worldwide.
During the virtual conference, which will take
place September 14-16, 2020, Oxurion will also be participating in
one-on-one sessions.
END
For further information please
contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer HallTel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation, standard of
care therapies to better preserve vision in patients with diabetic
macular edema (DME), the leading cause of vision loss in diabetic
patients worldwide.
Oxurion is building a leading global franchise
in the treatment of DME, based on the successful development of its
two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor being
developed as a potential new standard of care for DME patients who
respond sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Phase 1
results for the treatment of DME. The Company is currently
conducting a Phase 2 clinical trial evaluating THR-149 with
DME-patients who previously responded sub-optimally to anti-VEGF
therapy. THR-149 was developed in conjunction with Bicycle
Therapeutics PLC (NASDAQ: BCYC)
- THR-687, is a pan-RGD integrin inhibitor, that is initially
being developed as a potential new standard of care for all DME
patients. Positive topline results in a Phase 1 clinical study
assessing it as a treatment for DME were announced in January 2020.
THR-687 is expected to enter a Phase 2 clinical trial by
mid-2021.
THR-687 is an optimized compound derived from a broader library
of integrin inhibitors in-licensed from Galapagos NV (Euronext
& NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and is listed on
the Euronext Brussels exchange under the symbol OXUR.
More information is available at
www.oxurion.com.
Important information about
forward-looking statementsCertain statements in this press
release may be considered “forward-looking”. Such forward-looking
statements are based on current expectations, and, accordingly,
entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such
forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or any other
reason. Additional information concerning risks and uncertainties
affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is
contained in the Company’s Annual Report. This press release does
not constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mag 2023 a Mag 2024